It's no secret that exercise benefits both the mind and body, and it's increasingly being recognized as a powerful tool for ...
RMAT designation is based on promising Phase 2 clinical data demonstrating NG01’s potential to reduce disability and ...
As Bob Iger works his way through his final day in Disney's corner office, the outgoing CEO will leave behind a legacy that ...
On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027In a July 2025 Type B meeting, aligned ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results